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The global increase in multidrug resistant (MDR) bacteria has led to phage therapy being
refocused upon. A novel endolysin, LysPA26, containing a lysozyme-like domain, was
screened against Pseudomonas aeruginosa in this study. It had activity against MDR
P. aeruginosa without pretreatment with an outer-membrane permeabilizer. LysPA26
could kill up to 4 log units P. aeruginosa in 30 min. In addition, temperature and
pH effect assays revealed that LysPA26 had good stability over a broad range of
pH and temperatures. Moreover, LysPA26 could kill other Gram-negative bacteria,
such as Klebsiella pneumonia, Acinetobacter baumannii and Escherichia coli, but not
Gram-positive bacteria. Furthermore, LysPA26 could eliminate P. aeruginosa in biofilm
formation. Our current results show that LysPA26 is a new and promising antimicrobial
agent for the combat of Gram-negative pathogens.
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INTRODUCTION
Multidrug resistant bacteria, resistant to three or more classes of antimicrobial agent, have been
an increasing threat throughout the world in recent years (Li and Vederas, 2009; Young and Gill,
2015). Pseudomonas aeruginosa, an opportunistic pathogen, is among the most commonly isolated
MDR bacteria in clinical samples. P. aeruginosa, with its presence in extensive environmental
niches and its adaptive strategy (Lyczak et al., 2000), may be apt to take up plasmids and genes
that give multidrug resistance and increase its ability against those antibiotics used clinically (Li
et al., 2015; Boss et al., 2016). In addition, the biofilm formation of P. aeruginosa is also a form of
bacterial resistance mechanism to make it tolerant to conventional antibiotics (del Pozo and Patel,
2007). So, finding a new and effective method to combat the growing number of drug-resistant
bacteria is urgent.
The first bacteriophage described in the literature and responsible for the lysin activity was
in Twort (1915). Later bacteriophages and bacteriophage-derived products have been employed
in the treatment of bacterial infections (Hermoso et al., 2007; Keen, 2012), which has provided
an alternative strategy for combating MDR infections. Lysins, phage-lytic or phage-associated
enzymes produced by bacteriophages, have natural properties that can cause rapid bacterial
cell lysis by efficiently disrupting the peptidoglycan layer (Schuch et al., 2002). Over the past
Abbreviations: BLAST, Basic Local Alignment Search Tool; CFU, colony forming unit; EDTA, ethylene diamine
tetraacetic acid; MDR, multidrug resistant; NCBI, National Center for Biotechnology Information; OMP, outer-membrane
permeabilizer; ORF, open reading frame.
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few decades, there has been much research on the lysins
controlling bacteria both in vivo and in vitro (Nelson et al.,
2001; Alemayehu et al., 2012). The results showed that lysins
could work effectively against Gram-positive bacteria, but were
less effective against Gram-negatives due to the protective outer-
membrane barrier (Fischetti, 2005). However, if the bacteria
were pretreated with OMPs, such as EDTA, Triton X-100, or
trichloromethane (CHCl3) (Vaara, 1992; Helander and Mattila-
Sandholm, 2000), lysins could have an effect on Gram-negative
bacteria.
The application of lysins to combat MDR P. aeruginosa
strains, such as EL188 (Briers et al., 2011), KZ144 (Paradis-Bleau
et al., 2007), and OBPgp279 (Walmagh et al., 2012), has been
reported. Among these lysins, OBPgp279 was the first reported
endolysin that had an antimicrobial activity against P. aeruginosa
strains in the absence of OMPs (Walmagh et al., 2012). The
use of bacteriophages in combating biofilms comprises two
strategies, one is to prevent biofilm formation, and the other
is to disrupt existing biofilm (Azeredo and Sutherland, 2008).
Research by Pires et al. (2011) showed that phage phiIB-PAA2
could destroy P. aeruginosa PAO1 biofilm cells, and M4 phage
lysate was identified as having the ability to reduce P. aeruginosa
biofilm formation on catheter surfaces (Fu et al., 2010). In this
study, bacteriophage JD010 of P. aeruginosa was isolated and
its endolysin, named LysPA26, was purified. Our results showed
that LysPA26 has an intrinsic antimicrobial activity against
P. aeruginosa. Moreover, it also has an effect on some other
Gram-negative bacteria, such as Escherichia coli and Klebsiella
pneumoniae.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
The clinical strains P. aeruginosa, Acinetobacter baumannii,
E. coli, K. pneumoniae, and Staphylococcus aureus, isolated from
Ruijin Hospital (Shanghai, China), are shown in Supplementary
Table S1. All of these isolates were recorded in a computerized
database that included source and antimicrobial data. All the
bacteria were routinely cultured in LB medium. E. coli DH5α and
E. coli BL21(DE3) were grown in LB broth at 37◦C. When needed,
50 ng/ml of kanamycin was added to the growth medium.
Phage Isolation, Transmission Electron
Microscopy, and Genome Analysis
Phage particles were isolated from sewage obtained from
Ruijin Hospital (Shanghai, China) by five rounds of plaque
purification. Phage JD010 were purified by precipitation with
PEG 8000, followed by cesium chloride (CsCl) density-gradient
ultracentrifugation. The morphology of phage JD010 was
examined after staining with 2% phosphotungstic acid and using
a Hitachi 700 transmission electron microscope. The phage DNA
was extracted as described elsewhere (Lin et al., 2010) and
sequenced with an Illumina MiSeq platform. Using the BLAST
at the NCBI1, comparative genome analysis of phage JD010 was
1http://www.ncbi.nlm.nih.gov/BLAST/
carried out; the prediction of the conserved protein domain was
conducted using BLASTP and the NCBI Conserved Domain
Database2.
Overexpression and Purification of
LysPA26 Recombinant Protein
lysPA26 was amplified with the primers lysPA26-F/lysPA26-R
(the BamHI/XhoI restriction enzyme sites are shown in bold in
the primer sequences in Supplementary Table S2) with JD010
phage genomic DNA as the template. To construct the LysPA26
expression plasmid, the PCR product and vector pET28b were
digested with BamHI and XhoI restriction enzymes (Fermentas,
USA), then the PCR restriction fragment was ligated into the
pET28b vector (Supplementary Table S2) at the corresponding
restriction sites. After ligation, pET28b-lysPA26 plasmid was used
to transform E. coli BL21(DE3), and expression was induced with
1 mM isopropyl-β-D-thiogalactopyranoside for 5 h at 25◦C.
Anti-P. aeruginosa Activity Assay
Antimicrobial activity was determined as described previously
(Rodriguez et al., 2011) with some modifications. Briefly,
P. aeruginosa D204 was grown in LB broth at 37◦C to exponential
phase. Bacterial culture was harvested at 4000 g for 5 min
and washed once with dilution buffer (20 mM Tris-HCl, pH
8.0). Then, the cell pellet was resuspended in dilution buffer
and adjusted OD600 to 1.0. For the antimicrobial activity
assay, different concentrations of LysPA26 were added into
P. aeruginosa D204 bacterial suspension with or without OMPs
(EDTA, Triton X-100, or CHCl3). After 30 min of incubation at
37◦C, the mixture was serially diluted and plated. To determine
the survival rate, residual viable cell numbers (CFUs) on the
plate were measured after incubation at 37◦C for 24 h. For the
negative control, the same volume of buffer was added instead of
endolysin LysPA26. The antibacterial activity was expressed as the
decrease in viable bacterial counts. Alternatively, the antibacterial
activity was presented as the relative inactivation in logarithmic
units [= log10(N0/Ni), where N0 = the number of residual cells
(in the negative control) and Ni = the number of viable cells
counted after incubation with endolysin]. All experiments were
performed in triplicate.
Optimum Conditions for LysPA26 Activity
To study the effect of temperature on the activity of LysPA26,
50 µg LysPA26 was added into 100 µl test bacteria suspension,
and the mixture was incubated for 30 min at different
temperatures. For the thermal stability assay of LysPA26, the
endolysin was incubated at 100◦C for 10 min, then the heat-
treated LysPA26 was added into the P. aeruginosa D204 bacteria
suspension with or without 1 mM EDTA. The antibacterial
activities were measured as described above. To evaluate the effect
of pH on lytic activity, 10 µl LysPA26 (5 mg/ml) was incubated
with 90 µl buffers with different pH ranges (50 mM sodium
acetate for pH 4.0–6.0 and 20 mM Tris-HCl for pH 7.0–11.0) for
30 min. The effect of saline concentrations on the lytic activity of
2http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi
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LysPA26 was tested by adding different NaCl concentrations to
cell suspensions for 30 min in 20 mM Tris-HCl buffer, pH 7.0, at
37◦C. The residual activity of each treatment group relative to the
activity of the control group (100% activity) was determined. All
experiments were performed in triplicate.
Determination of the Lytic Range of
LysPA26
To test the lytic zymogram range of LysPA26, P. aeruginosa,
A. baumannii, E. coli, K. pneumoniae, and S. aureus isolates were
challenged. All isolates, in mid-exponential phase, were washed
and resuspended in dilution buffer (20 mM Tris-HCl, pH 8.0),
50 µg LysPA26 was incubated with the various bacterial species
isolates in a final volume of 100 µl, and then serial dilutions of
the samples were plated for CFU counting after incubation for
30 min; antibacterial activities were measured as described above.
All experiments were performed in triplicate.
Anti-biofilm Properties
The biofilm eradication assay was carried out by crystal violet
staining as described previously (Sass and Bierbaum, 2007).
MDR P. aeruginosa strain 8328 was cultured in the wells of
a polystyrene 96-well plate (BD Falcon) at 37◦C for 48 h to
allow biofilm formation. The planktonic cells in the culture were
discarded and the plate washed with phosphate-buffered saline
three times. LysPA26 (100 µg in 200 µl) was added to the
plate wells, incubated at 37◦C for 2 h, and then washed twice
with phosphate-buffered saline. Crystal violet (100 µl 1%) was
added and incubated for 30 min; subsequently, 33% acetic acid
was added to dissolve the stain, and the optical density was
measured at OD600. The elimination activity of LysPA26 was
also measured by enumerating the reduction of the residual live
biofilm cells (Fu et al., 2010). Briefly, after discarding planktonic
cells, the biofilm cells were treated with LysPA26 for 2 h. The
contents of the treated biofilm-containing wells were mixed
fully with a pipetting device, followed by sonication at 42 kHz
in a water bath sonicator to make the biofilm cells become
planktonic cells. For each experiment, samples were analyzed in
triplicate.
Statistical Analyses
Data were analyzed by a Student’s t-test, and a value of P < 0.05
was considered statistically significant.
RESULTS
Isolation and Characterization of Phage
JD010
A phage, named JD010, was isolated from sewage water in Ruijin
Hospital (Shanghai, China). Based on electron microscopy, phage
JD010 was classified as a member of family Podoviridae with
15 nm tail length and 50 nm head width (Figure 1A). Phage
JD010 DNA was obtained and sequenced. Phage JD010 has
a double-stranded DNA genome of 50609 bp containing 75
ORFs, with a G+C content of 55.5% (Figure 1B). BLAST
FIGURE 1 | Characterization of bacteriophage JD010. (A) Scanning
electron microscopy image of phage JD010, negatively stained with 0.2%
phosphotungstic acid. The scale bar represents 100 nm. (B) Genome
organization map of phage JD010. The arrows in the figure indicate the
predicted ORF of the phage genome. The red arrow points to the endolysin
gene.
analysis showed that the JD010 genome had sequence similarity
with Pseudomonas phage PA11, with 89% identity and 83%
coverage. ORF 26 of the phage JD010 genome was predicted
as the putative endolysin and named LysPA26. BLAST analysis
revealed LysPA26 was homologous to the endolysin (ORF033) of
Pseudomonas phage PA11, with 99% amino acid identity.
Cloning and Purification of LysPA26
LysPA26 was predicted to belong to the lysozyme-like domain
family of superfamily cd00442, which work as peptidoglycan
hydrolases. A comprehensive bioinformatics study showed that
LysPA26 was composed of a single conserved sequence motif
(lysozyme domain), involving the sequence from the 6th to
138th amino acids of the 145 amino acids. The catalytic residues
(active sites) of LysPA26 were predicted to be E13 (Glu) and T28
(Thr) (Figure 2A). Recombinant LysPA26 was overexpressed and
successfully purified from the soluble fraction (Figure 2B).
Antibacterial Activity of LysPA26
To verify the antibacterial activity of LysPA26, P. aeruginosa
D204 was challenged with different concentrations of
LysPA26. LysPA26 showed efficient bactericidal activity against
exponentially growing P. aeruginosa D204, and its antibacterial
activity was enhanced as the concentration increased (Figure 3).
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FIGURE 2 | Expression and characterization of LysPA26. (A) Schematic diagram of the domain organization of LysPA26. The predicted lysozyme-like domain is
marked in dark gray, and involves amino acids 6–138. (B) SDS-PAGE gel (15%) of samples from the purification process of LysPA26. Lane 1, molecular size ladder;
lane 2, crude lysate extract of BL21(DE3) before induction; lane 3, crude lysate from isopropyl-β-D-thiogalactopyranoside-induced bacteria; lane 4, the purified
LysPA26 (21 kDa).
It was interesting that LysPA26 could kill P. aeruginosa D204
without an OMP. The lytic ability of LysPA26 did not increase
any further when the concentration of LysPA26 was more than
0.5 mg/ml. Thus, the endolysin concentration of 0.5 mg/ml was
used in the following assays.
With pre-treatment by OMPs, such as EDTA, Triton X-
100, or CHCl3, lysin can effectively destroy Gram-negative
bacteria as reported. In order to test the effect of OMPs on
the bactericidal activity of LysPA26, EDTA, Triton X-100, and
CHCl3 were selected to individually pretreat P. aeruginosa D204,
and antibacterial activity was expressed as the decrease in viable
bacterial counts (Figures 4A–C). Different concentrations of
OMPs were tested to determine whether they had synergistic
effects on the antimicrobial activity of LysPA26. The results
showed the EDTA could enhance the lytic ability of LysPA26
against P. aeruginosa D204 in a certain range, but Triton X-100
and CHCl3 could not. Thus, 1 mM EDTA was selected for use as
the OMP in the following experiments, where needed.
Determination of Optimal Conditions for
the Activity of Endolysin LysPA26
The optimal conditions for the bactericidal activity of LysPA26,
such as temperature, pH, and saline concentration, were tested.
Temperature was the key factor affecting the bactericidal activity
of endolysin. As shown in Figure 5A, LysPA26 exhibited high
antibacterial activity from 37 to 50◦C. The antibacterial activity
of LysPA26 decreased when the temperature was lower than 25◦C
or higher than 60◦C. As for the effect of saline concentration on
the activity of LysPA26, NaCl was selected for the test. The results
showed that a NaCl concentration below 150 mM did not show a
significant effect on the activity of LysPA26. However, when the
concentration was high enough, up to 300 mM, it could reduce
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FIGURE 3 | Antimicrobial activity assay of LysPA26. Different
concentrations of LysPA26 (0.05, 0.2, 0.5, 1 mg/ml) were added to washed
Pseudomonas aeruginosa D204 cells resuspended in incubation buffer
(20 mM Tris-HCl, pH 8.0). The residual cell CFU number of P. aeruginosa
treated by LysPA26 was counted and presented as the relative inactivation.
Error bars represent the standard deviations of three independent assays.
the efficacy of LysPA26 (Figure 5B). As for the effect of pH on
activity of LysPA26, it was efficiently active from pH 6.0 to 8.0,
and the optimal pH was 8.0 (Figure 5C). The results showed
the LysPA26 has a good pH stability in the antibacterial activity
assay.
We also checked the thermostability of LysPA26, it was heat-
treated at 100◦C for 10 min before being used to challenge
exponentially growing P. aeruginosa D204; the cells were treated
with EDTA or were untreated. For the challenged bacteria
without EDTA treatment, the activity of LysPA26 decreased to
less than 20%. However, when treated with the EDTA, LysPA26
still maintained over 90% of its activity (Figure 5D). This
may be attributed to the stability of LysPA26 catalytic sites
and the reliable permeabilization of EDTA, which makes the
peptidoglycan fully exposed.
LysPA26 Shows an Antibacterial
Spectrum against more MDR
Gram-Negative Species Besides its Host
Strain
To further estimate the zymogram range of LysPA26 against
clinical MDR strains, clinical samples including Gram-negative
(A. baumannii, K. pneumoniae, P. aeruginosa, and E. coli)
and Gram-positive (S. aureus) bacteria were tested. LysPA26
exhibited high antibacterial activity against the tested Gram-
negative bacteria (Figure 6). It was apparent that the antibacterial
spectrum of LysPA26 was broader than phage JD010. Of note,
LysPA26 could not kill P. aeruginosa A2210, which is the host
of JD010. A methicillin-resistant S. aureus isolate was tested to
detect the antibacterial activity of LysPA26 against Gram-positive
bacteria. The results showed no antibacterial activity against the
strain.
LysPA26 Is able to kill P. aeruginosa in
Biofilms
Pseudomonas aeruginosa is one of the most common biofilm-
forming bacteria. We designed experiments to test whether
LysPA26 had the ability to destroy P. aeruginosa biofilm.
P. aeruginosa 8328 was attached to a plate for 48 h to form biofilm
before adding LysPA26. We found that the LysPA26 had the
ability to efficiently destroy existing biofilm cells. The elimination
ability of biofilm was dose dependent; the optical density (OD600)
staining of the biofilms was reduced significantly upon addition
of LysPA26 up to 50 µg (Figure 7A). Approximately 1–2 log in
the number of viable counts of biofilm cells in the plate wells was
disrupted by LysPA26 (100 µg) (Figure 7B). Combined with the
other results, the elimination efficiency for the biofilm cells was
comparatively lower than that for the planktonic cells.
DISCUSSION
Multidrug resistant bacteria, such as P. aeruginosa, A. baumannii,
K. pneumonia and S. aureus, have been an increasing threat
FIGURE 4 | The synergistic antimicrobial activity assay of LysPA26 and OMPs. (A) The effect of the concentration of EDTA on the lytic activity of LysPA26.
The antimicrobial activity of LysPA26 (0.5 mg/ml) was checked under different concentrations of EDTA (0, 1, 5 mM). (B) The effect of the concentration of Triton
X-100 on the lytic activity of LysPA26. The antimicrobial activity of LysPA26 (0.5 mg/ml) was checked under different concentrations of Triton X-100 (0, 0.01, 0.1,
1%). (C) The effect of the concentration of CHCl3 on the lytic activity of LysPA26. The antimicrobial activity of LysPA26 (0.5 mg/ml) was checked under different
concentrations of CHCl3 (0, 0.001, 0.01, 0.1, 1%). After 30 min of incubation, the residual viable cells were plated and the decrease in viable bacterial numbers
measured. Error bars represent the standard deviations of three independent assays.
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FIGURE 5 | Influence of temperature, NaCl and pH conditions on the bactericidal activity of LysPA26. (A) The effects of temperature on the lytic activity of
LysPA26. LysPA26 (0.5 mg/ml) was added to test bacterial suspensions and incubated for 30 min at different temperatures to determine the bactericidal assay.
(B) The influence of saline concentration on the bactericidal activity of LysPA26. LysPA26 (0.5 mg/ml) was added to test bacterial suspensions under different NaCl
concentrations to determine the antimicrobial activity. (C) The influence of pH on the lytic activity of LysPA26. LysPA26 (0.5 mg/ml) was incubated with buffers with
different pH values (50 mM sodium acetate for pH 4.0–6.0 and 20 mM Tris-HCl for pH 7.0–11.0) for 30 min to determine the antimicrobial activity.
(D) Thermo-stability of LysPA26. LysPA26 (0.5 mg/ml) was incubated at 100◦C for 10 min before determining the antimicrobial activity in the absence of EDTA or
with 1 mM EDTA. Bactericidal activity is presented as the relative inactivation. Error bars represented the standard deviations of three independent assays.
FIGURE 6 | The antimicrobial spectrum of the LysPA26. Bacteria, including both Gram-negative and Gram-positive bacteria, were examined. For all the
challenged isolates, 0.5 mg/ml LysPA26 was added into the bacteria suspension after 30 min incubation at 37◦C. The antibacterial activity was expressed as the
decrease in viable bacterial numbers. Error bars represent the standard deviations of three independent assays.
Frontiers in Microbiology | www.frontiersin.org 6 February 2017 | Volume 8 | Article 293
fmicb-08-00293 February 23, 2017 Time: 19:47 # 7
Guo et al. A Novel Antimicrobial Endolysin
FIGURE 7 | Biofilm eradication ability of LysPA26. Biofilm was grown on a polystyrene plate. (A) Biofilm eradication ability was determined by optical density
analysis. (B) Eradication ability of LysPA26 was expressed as the discrepancy of the number of viable cells in the different treatments. ∗∗∗ Indicates significant
difference (P < 0.001). Error bars represent the standard deviations of three independent assays.
throughout the world in recent years. The emergence and
dissemination of MDR strains of various bacteria species has
posed a big challenge for effective clinical treatment. This
constantly emerging phenomenon of MDR bacteria has renewed
interest in the use of phages as antimicrobial agents (Pires et al.,
2016).
There has been much research of phage lysins, and most of
it has been with Gram-positive pathogens. Phage lysins have
been shown to be ineffective against Gram-negative bacteria by
direct exogenous application, because of the protective outer-
membrane barrier in these bacteria (Fischetti, 2005, 2010). If
cells were pretreated with an OMP, such as EDTA or Triton X-
100, the lysins can destroy Gram-negative bacteria (Briers et al.,
2014). Nevertheless, recent published data supports the idea that
some natural lysins have intrinsic antibacterial activity against
Gram-negative bacteria in the absence of an OMP, for example
endolysin LysAB21 and PlyF307 from A. baumannii phage (Lai
et al., 2011; Lood et al., 2015), and endolysin OBPgp279 from
Pseudomonas fluorescens phage OBP (Walmagh et al., 2012).
Basic Local Alignment Search Tool analysis of publically
available data confirmed that LysPA26 has only one homolog,
gene ORF033 of Pseudomonas phage PA11 (Kwan et al., 2006),
but its features have not been reported. Unlike some other
Gram-negative endolysins possessing an N-terminal binding
domain and a C-terminal catalytic domain (Briers et al., 2011;
Walmagh et al., 2013), LysPA26 is a single domain endolysin.
In this study, we found that 0.5 mg/ml LysPA26 could kill
about 4 log unit bacteria in 30 min when incubated with 108
exponential cells of host bacteria P. aeruginosa D204, and the
reaction was in the absence of EDTA. When the challenged
cells were pretreated by the addition of 1 mM EDTA, the
bacteria were more sensitive. For the same reaction, more than
1 log cells were killed by endolysin LysPA26, suggesting that
EDTA enhanced the antibacterial capacity of LysPA26, which
has been reported previously (Lim et al., 2014; Oliveira et al.,
2014). However, when 5 mM EDTA was added, the greater
addition of EDTA did not enhance the LysPA26 to further
reduce the number of viable P. aeruginosa D204 cells, a similar
effect was described with SPN9CC endolysin from SPN9CC
phage against Salmonella Typhimurium, which could kill intact
Gram-negative bacteria in the absence of EDTA (Lim et al.,
2014).
The pH test for endolysin LysPA26 showed that LysPA26 was
stable at a broad pH range (5.0–9.0), which is a good feature
required for promising antimicrobial agents. Its optimal pH was
around 8.0. Temperature tests of LysPA26 showed that LysPA26
retained high activity (relative antibacterial activity > 90%)
against P. aeruginosa D204 at 50◦C. Unexpectedly, we found
that LysPA26 still exerted a high bactericidal activity against
the outer-membrane permeabilized isolates under heat treatment
at 100◦C. Some Gram-negative bacterial endolysins in previous
studies showed good thermostability, for example endolysins
KZ144 and EL188 from Pseudomonas phage could retain high
activity at 50◦C (Briers et al., 2007). PVP-SE1gp146, described as
the first thermo-resistant Gram-negative phage endolysin from
P. aeruginosa PAO1, could maintain activity at temperatures up
to 90◦C (Walmagh et al., 2012). BLAST analysis revealed that
there was no significant similarity between PVP-SE1gp146 and
LysPA26, although both of them have thermo-resistance. We
presumed that for both of them, their thermo-resistance can
likely be attributed to their stable conformational structure.
In our results, LysPA26 could not only kill P. aeruginosa
efficiently, but also combat other Gram-negative species,
such as E. coli, and K. pneumoniae, which are among the
most drug-resistant Gram-negative pathogens. However, it was
ineffective against Gram-positive bacteria, such as S. aureus. We
suspect that the peptidoglycan layer of Gram-positive strains
is not susceptible to endolysin LysPA26. This characteristic
makes LysPA26 a promising candidate for selectively treating
Gram-negative species.
Bacterial biofilm is a type of survival strategy for resisting
the host defense mechanism or sub-optimal environmental
conditions (Donlan and Costerton, 2002). Due to the increased
tolerance to antibiotic treatment, many clinical complications
associated with numerous biofilm-forming pathogens are very
difficult to treat (Costerton et al., 1999). Bacteriophages
and bacteriophage-enzyme-based strategies for prevention and
eradication of biofilm bacteria have been extensively studied
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and proposed to be a promising bio-control method against
bacteria (Xavier et al., 2005). The biofilm-disrupting activity
experiment in this study showed that LysPA26 exhibited the
ability to disrupt P. aeruginosa in biofilm form and degraded
biofilms in a concentration-dependent manner.
Although further investigation and additional experiments
are needed to explain the efficacy and the lytic mechanism
of LysPA26, it is undoubtable that LysPA26 is a novel and
promising agent for directly combating MDR P. aeruginosa in
the planktonic form, as well as in the biofilm form. This endolysin
could be a desirable candidate for use as a bio-control tool against
Gram-negative pathogen infection.
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